Detail akcie CaptorTher Br-Reg S online

Business Summary: Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Captor Therapeutics SA revenues decreased 64% to PLN4.6M. Net loss increased 8% to PLN32M. Revenues reflect Research and Development segment decrease of 80% to PLN2.6M. Higher net loss reflects Research and Development segment loss increase of 10% to PLN33.3M. Basic Earnings per Share excluding Extraordinary Items increased from -PLN6.36 to -PLN5.79.